For Release: 15 December 2010
Advanced Medical Solutions Group plc
(“AMS” or the “Company”)
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, today announces an update on trading prior to its close period for the year ending 31 December 2010.
AMS reports that the positive progress reported at the Interims has continued and current indications for the full year are that AMS will be at the top end of market expectations.
Sales of its LiquiBand® products in the US continue to see good momentum and will be ahead of the Company’s expectations in the current year. Sales have benefited in this launch year from demand arising from sampling and customer evaluations. Even allowing for this, AMS is very pleased with the progress made.
Dr. Geoffrey Vernon, Chairman of AMS, stated: “As I approach the end of my time as Chairman, I am pleased to report that AMS continues to make good progress. I am confident that the business is on a sound footing for the next stage of its development and I would like to take this opportunity to wish the Company well and to thank all AMS employees for their support and hard work over the ten years that I have been Chairman.”
– ends –
For further enquiries:
Advanced Medical Solutions Group plc +44 (0) 1606 545508
Don Evans, Chief Executive Officer
Chris Meredith, Chief Operating Officer
Mary Tavener, Finance Director
Tavistock Communications +44 (0) 20 7920 3150
John West / Chris Munden / Andrew Dunn / Lydia Eades
Investec Bank plc +44 (0) 20 7597 5970
Gary Clarence / Patrick Robb / Daniel Adams
Notes to Editors:
AMS’ advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foams. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They protect the wound, deal with tissue fluids and provide an optimal environment for healing to occur. Silver is widely recognised as a safe and effective broad-spectrum anti-microbial agent for infection control.
AMS’ wound closure and sealants products are based on cyanoacrylate adhesive (“superglue”) technology developed for medical applications. Tissue adhesives offer significant benefits over conventional ways of closing wounds following trauma or surgical incision. They are simple to use, non-invasive, help to reduce the risk of infection, minimise trauma to the patient and provide good clinical and cosmetic outcomes. The technology is also ideally suited to protecting skin from breakdown or for use as a skin sealant to help prevent infection of surgical sites.
AMS employs 240 people in three locations (Winsford, Plymouth and the Netherlands). The business has an experienced management team, whose stated aim is to grow the business both organically and by exploring selective acquisition opportunities. The Board has announced its intention to recommend a maiden dividend for the year ended 31st December 2010.
This information is provided by RNS